Who
Glenn P. Muir
Director
Company insider
Files Form 4 as: Director, Cytek Biosciences; Director, Neuronetics; Director, Repligen; Director, G1 Therapeutics; Director, Lifeward; Executive VP and CFO, Hologic.
In numbers
- Trades disclosed
- 228
- Buys
- 9
- Sells
- 25
- Bought
- $2.2M
- Sold
- $27.1M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 1 Feb 2006
- Last trade
- 18 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 20 Aug 2026 | CTKB Cytek BiosciencesLife-science tools | SEC FORM 4 Code M | —3,086 | filing |
| 18 Aug 2026filed 20 Aug 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code M | —3,086 at $0.00 | filing |
| 18 Aug 2026filed 20 Aug 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code M | —3,086 at $0.00 | filing |
| 18 Aug 2026filed 20 Aug 2026 | CTKB Cytek BiosciencesLife-science tools | SEC FORM 4 Code M | —3,086 | filing |
| 10 Jun 2026filed 12 Jun 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code A | —55,555 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code A | —29,835 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code A | —55,555 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | CTKB Cytek Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code A | —29,835 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | STIM NeuroneticsMedical Devices | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | STIM NeuroneticsMedical Devices | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code A | —995 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,239 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,239 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code A | —995 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code M | $94K2,434 at $38.76 | filing |
| 7 May 2026filed 8 May 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,434 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,434 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code M | $94K2,434 at $38.76 | filing |
| 16 Dec 2025filed 17 Dec 2025 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,366 at $0.00 | filing |
| 16 Dec 2025filed 17 Dec 2025 | RGEN RepligenBiotechnology | SEC FORM 4 Code M | $88K3,366 at $26.12 | filing |
News
Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference CallSTIM · manilatimes.net · 21 Oct 2026
0 headlines in the last 90 days name Glenn P. Muir; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.